On January 15, 2026, the updated EC guidelines on the details of the various categories of variations applies. This change brings both clarifications and practical improvements for managing post-approval changes to human medicinal products. It’s part of a broader shift toward risk-based, science-driven regulation – something we’ll see even more of with the upcoming ICH M4Q(R2) guideline.
EC variation guideline – what’s new?
Focus on human medicines: Veterinary content is now excluded, as separate guidelines now apply to animal products.
Reclassification to lighter variation types: Some changes previously classified as Type II may now be Type IB or even IA, depending on risk. For example, changes to – or extensions of – a design space can now be submitted by Type IB variation instead of Type II.
More information on documentation requirements: For certain changes, documentation expectations have been further specified. For example, for CEP-related changes, the guideline now describes e.g. need for provision of batch results from testing carried out by the holder/finished product manufacturer.
Clearer rules for drug-device combinations: New classifications have been added for changes relating to devices with the medicinal product
Article 5 recommendations integrated: Some of the previously separate recommendations are now part of the guideline.
Clarification on classification: For certain variations, the guideline now specifies the types of changes for which each variation category is intended. Examples include:
- Updates to Certificates of Suitability (CEP): Certain CEP-related changes, such as adding a new micronisation site not included in the CEP or updating in-house methods used by the finished product manufacturer – the CEP variation classifications now include an informative note specifying which variation categories apply to micronisation site or update of in-house methods, thereby clarifying how they should be submitted.
- Removal of non-significant or obsolete specification attribute: The Type IA variation for removing of e.g. tests for odor, taste, or color identification now includes a condition that the change must not relate to a revision of the control strategy with an intention to minimise testing of parameters and attributes (critical or non-critical).
Further reading
- New variation guidelines in the EC’s Official Journal
- Type II changes to manufacturing sites or batch sizes of finished product manufactured by complex manufacturing processes: Interpretation of what constitutes a “complex” manufacturing process is provided in Quality of medicines questions and answers: Part 1 | European Medicines Agency (EMA) (e.g. ATMPs, liposomal preparations, nanoparticulate preparations.) If a change would be submitted as a Type IB variation, the applicant would have to provide a justification why the manufacturing process is not considered complex as per the interpretation.
- Additional guidance on classification: Further advice is available in the EMA document 01. Classification of changes
- Updated variation stability guideline: GL on Stability Testing for Applications for Variations to a Marketing Authorisation provides general requirements for stability data needed to support variations to human medicinal products.
You may have experienced increased workload in variation submissions while aiming to file all variations under the previous guideline within the required timeline before 15 January 2026. In some cases, determining the correct classification may also have required deeper consideration.
If, when working with the new variation classification guideline, you find that you need an expert who can quickly assess the appropriate classification for your variations – or if you would appreciate support with writing urgent variation applications – Medfiles’ CMC experts are happy to assist. We can write your variation documentation and help design the optimal variation strategy to ensure smooth implementation of changes in accordance with the new guidelines. Medfiles’ experts consult in studies needed to support the change and take care of the regulatory activities and eSubmission. You will receive a comprehensive marketing authorisation maintenance service for your medicinal products.
Author: Eeva-Maija Walin, Senior Pharmaceutical Chemical Expert
Eeva-Maija Walin has worked at Medfiles since 2019 as a Senior Pharmaceutical Chemical (CMC) Expert. She holds an M.Sc. in Chemistry and has further broadened her expertise through studies in pharmacy and microbiology at open universities. Prior to joining Medfiles, Eeva-Maija worked for almost 20 years in various CMC expert roles within the pharmaceutical industry.
She has extensive experience in CMC documentation for new marketing authorisation applications and post-approval variations submitted to EU medicines authorities and the FDA. Her expertise includes preparation of quality summaries, evaluation of client documentation against regulatory requirements (gap analyses), and advising on GMP-related matters. At Medfiles, Eeva-Maija supports clients in a wide range of drug development and lifecycle management projects for both human and veterinary medicinal products, drawing on her strong background in pharmaceutical development, quality documentation and regulatory compliance.
Author: Ulla Orava, Head of Operations, CMC
Ulla Orava has worked at Medfiles since 2007. She has 25 years of experience from pharmaceutical development, product maintenance, marketing authorisation dossiers and post-approval variations. Before joining Medfiles, Ulla worked with assessment and coordination of variations at the Finnish Medicines Agency, as well as with drug product development and product maintenance in the pharmaceutical industry.
She has experience from planning pharmaceutical and chemical studies needed for global marketing authorisation applications as well as the guidelines steering these studies. In addition, Ulla has considerable competence in changes needed for drug products, problem solving, planning and classification of variations and writing variation documentation, not to forget a good grasp of how the authorities interpret variation guidelines. At Medfiles, Ulla’s roles as Head of CMC Operations, leading an extremely experienced team of CMC experts, and before that, as a CMC Expert, have allowed her to fully utilise her wide range of expertise in various drug development projects and in managing the quality dossiers for human and veterinary products and post-approval variation applications.
